Pan African Clinical Trials Registry
South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834 Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202602541023094 Date of Registration: 26/02/2026
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title Detection rate of ICG SLN in intermediate and high grade endometrial cancer
Official scientific title Detection rate of Indocyanine Green (ICG) sentinel lymph node in intermediate and high grade endometrial cancer
Brief summary describing the background and objectives of the trial Back ground: Endometrial cancer (EC) is the most common gynecological malignancy of the female genital tract in developed countries. In terms of mortality of female genital tract cancers, the rate of EC is the second highest worldwide. High-grade EC include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated/dedifferentiated carcinomas, and carcinosarcoma. They metastasize via the lymphatic system. In contrast, low-grade type 1 endometrioid carcinomas tend to remain confined to the uterus. Lymph node (LN) metastasis is the primary route of metastasis of malignant uterine tumors as well as the main recurrence cause and the main risk factors of lymphatic involvement are myometrial involvement and histologic grade. Lymph node assessment as a staging procedure has been clinically important in evaluating the disease extent and providing prognostic information, which may help in deciding adjuvant treatments. Lymphadenectomy in high-grade EC histotypes, was associated with improved overall and recurrence free survival. Regarding extensive systemic lymphadenectomy, A study of the treatment of cancer of the womb (ASTEC) trial and the Italian collaborative trial reported a considerable increase in lymphatic dissection complications (relative risk [RR]: 3.73; 95% CI: 1.04−13.27) and surgical morbidity (RR: 8.39; 95% CI: 4.06−17.33). Although SLNB has gained acceptance in the context of low-grade EC, its role in high-grade EC remains unclear. Fluorescent dye Indocyanine green (ICG), a safe and effective agent for SLN mapping, has emerged as the most recommended tracer for intraoperative detection of SLN in EC owing to its higher sensitivity and specificity compared with conventional tracers (blue dye and radiotracer). This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer.
Type of trial CCT
Acronym (If the trial has an acronym then please provide)
Disease(s) or condition(s) being studied Cancer
Sub-Disease(s) or condition(s) being studied
Purpose of the trial Detection rate of a certain material used in SLNB identification in cancer patient
Anticipated trial start date 01/01/2026
Actual trial start date 01/01/2026
Anticipated date of last follow up 31/12/2026
Actual Last follow-up date 31/12/2026
Anticipated target sample size (number of participants) 39
Actual target sample size (number of participants) 39
Recruitment status Active, not recruiting
Publication URL
Secondary Ids Issuing authority/Trial register
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Single Group Non-randomised Allocation Sequence/Code was not concealed Open-label(Masking Not Used)
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group Injection of ICG at cervix of endometrial cancer patient to detect sentinel lymph node one 25 mg vial of ICG powder will be reconstituted in 10mL of sterile water (2.5mg/ mL) and drawn into a spinal needle. sentinel lymph node will be traced after about 15 minutes in pelvic region and 30 minutes in abdominal region lymph node stained by ICG will be sent as a separate specimen for paraffin examination then traditional lymphadenectomy to be done 39
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
1- Patients (≥18 years of age) with FIGO stage IB and more grade II endometrioid EC and high-grade EC (grade 3 endometrioid, serous, carcinosarcoma, clear cell, undifferentiated or dedifferentiated, and mixed high grade) scheduled for laparoscopic primary hysterectomy with an intent to complete full staging. 2- Written informed consent. 3- Clinically node negative patients with no gross extra-uterine extension or peritoneal metastasis. 1- Grade I and FIGO stage 1A grade II endometrioid EC. 2- Recurrent, or suspected advanced EC (extra-uterine extension or clinically positive lymph nodes). 3- Prior retroperitoneal surgery or abdominopelvic radiotherapy. 4- Need for Neoadjuvant therapy. 5- Plans to omit lymphadenectomy based on surgical or anesthetic risk. 6- Pregnancy. 7- Iodide allergy. 80 and over: 80+ Year,Adolescent: 13 Year-18 Year,Adult: 19 Year-44 Year,Aged: 65+ Year(s),Middle Aged: 45 Year(s)-64 Year(s) 18 Year(s) 80 Year(s) Female
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 16/09/2024 Institutional Review Board IRB
Ethics Committee Address
Street address City Postal code Country
Al Gomhorya Street Mansoura 35516 Egypt
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 16/09/2024 Medical Research Ethics Committee Institutional Review Board Mansoura Faculty of Medicine Mansoura University
Ethics Committee Address
Street address City Postal code Country
Al Gomhorya street Mansoura 35516 Egypt
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 01/02/2026 Medical Research Ethics Committee Institutional Review Board
Ethics Committee Address
Street address City Postal code Country
AlGomhorya street Mansoura 35516 Egypt
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high-grade endometrial cancer. this outcome will be measured post operative after paraffin result both outcomes will be measured after paraffin result postoperatively
Secondary Outcome Determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. At the end of the study when all data of the participant collected and statistically analysed
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Oncology Center Mansoura University Gehan Al Sadat St Mansoura Egypt
FUNDING SOURCES
Name of source Street address City Postal code Country
Samar Abdallah Gehan Al sadat Street Mansoura Egypt
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor Oncology Center Mansoura University Gehan Al Sadat st Mansoura Egypt Hospital
COLLABORATORS
Name Street address City Postal code Country
CONTACT PEOPLE
Role Name Email Phone Street address
Scientific Enquiries Adel Fathi dr_adelfathi@outlook.com +201061116256 Al bahr St
City Postal code Country Position/Affiliation
Mansoura Egypt Prof of surgical oncology Oncology Center Mansoura University
Role Name Email Phone Street address
Principal Investigator Samar Abdallah samardohina28@gmail.com +201011667600 6 Al Qouds st
City Postal code Country Position/Affiliation
Mansoura Egypt Investigator at Oncology Center Mansoura University
Role Name Email Phone Street address
Public Enquiries Khaled Gaballa Dr_Kh_gaballah@hotmail.com +201005058056 Al Gomhorya st
City Postal code Country Position/Affiliation
Mansoura Egypt Associate professor of surgical oncology Oncology Center Mansoura University
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes All the individual participant data collected during this study will be available after deidentification. Also, study protocol and statistical analysis plan will be available immediately after publication. All will be available as both soft and hard copy at Faculty of medicine, Mansoura University library, Mansoura University Central Library and Alexandria Library Study Protocol within two years from now Endometrial Cancer, Sentinel lymph node, ICG, detection rate, lymphadenectomy
URL Results Available Results Summary Result Posting Date First Journal Publication Date
No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Public title 29/12/2025 As requested by the reviewer معدل الكشف عن العقد الليمفاوية الحارسة بواسطة خضرة الإندوسيانين في مريضات الدرجة المتوسطة والعالية من سرطان الرحم Detection rate of ICG SLN in intermediate and high grade endometrial cancer
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Trial description 29/12/2025 the reviewer asked for a brief background about the study This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. In this study, one 25 mg vial of ICG powder will be reconstituted in 10mL of sterile water (2.5mg/ mL) and drawn into a spinal needle. The cervix was injected at the 3- and 9-o'clock positions with 0.5 mL of IGC superficially (at 1- to 2-mm depth) and 0.5 mL of ICG deep (at 10-mm depth) for a total dose of 2 mL of ICG. Patients will undergo a standard algorithm for SLNB. In the first step, each hemi-pelvis will be assessed for successful mapping of a SLN. Surgeons will enter the retroperitoneum over the psoas muscle and identify lymph node channels and stations using the Karl Storz ENDOSKOPE ICG camera system with near-infrared spectroscopy (NIR) imaging. All green nodes and non-green nodes with green afferent lymphatic channels will be deemed SLN. Surgeon should retrieve SLNs within 10 minutes after injection of ICG. Then, SLN will be resected from mapped sides and will be send for paraffin, and locations will be noted by the surgeon on standardized intraoperative data collection forms. Total laparoscopic hysterectomy and bilateral salpingo-oophorectomy will be done. In the final step, patients will undergo standard lymphadenectomy bilateral pelvic only in intermediate grade and bilateral pelvic and paraaortic lymphadenectomy in high grade till inferior mesenteric artery.
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Trial description 14/01/2026 as the reviewer asked to add brief background This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. In this study, one 25 mg vial of ICG powder will be reconstituted in 10mL of sterile water (2.5mg/ mL) and drawn into a spinal needle. The cervix was injected at the 3- and 9-o'clock positions with 0.5 mL of IGC superficially (at 1- to 2-mm depth) and 0.5 mL of ICG deep (at 10-mm depth) for a total dose of 2 mL of ICG. Patients will undergo a standard algorithm for SLNB. In the first step, each hemi-pelvis will be assessed for successful mapping of a SLN. Surgeons will enter the retroperitoneum over the psoas muscle and identify lymph node channels and stations using the Karl Storz ENDOSKOPE ICG camera system with near-infrared spectroscopy (NIR) imaging. All green nodes and non-green nodes with green afferent lymphatic channels will be deemed SLN. Surgeon should retrieve SLNs within 10 minutes after injection of ICG. Then, SLN will be resected from mapped sides and will be send for paraffin, and locations will be noted by the surgeon on standardized intraoperative data collection forms. Total laparoscopic hysterectomy and bilateral salpingo-oophorectomy will be done. In the final step, patients will undergo standard lymphadenectomy bilateral pelvic only in intermediate grade and bilateral pelvic and paraaortic lymphadenectomy in high grade till inferior mesenteric artery. This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. Back ground: Endometrial cancer (EC) is the most common gynecological malignancy of the female genital tract in developed countries. In terms of mortality of female genital tract cancers, the rate of EC is the second highest worldwide. High-grade EC include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated/dedifferentiated carcinomas, and carcinosarcoma. They metastasize via the lymphatic system. In contrast, low-grade type 1 endometrioid carcinomas tend to remain confined to the uterus. Lymph node (LN) metastasis is the primary route of metastasis of malignant uterine tumors as well as the main recurrence cause and the main risk factors of lymphatic involvement are myometrial involvement and histologic grade. Lymph node assessment as a staging procedure has been clinically important in evaluating the disease extent and providing prognostic information, which may help in deciding adjuvant treatments. Lymphadenectomy in high-grade EC histotypes, was associated with improved overall and recurrence free survival. Regarding extensive systemic lymphadenectomy, A study of the treatment of cancer of the womb (ASTEC) trial and the Italian collaborative trial reported a considerable increase in lymphatic dissection complications (relative risk [RR]: 3.73; 95% CI: 1.04−13.27) and surgical morbidity (RR: 8.39; 95% CI: 4.06−17.33). Although SLNB has gained acceptance in the context of low-grade EC, its role in high-grade EC remains unclear. Fluorescent dye Indocyanine green (ICG), a safe and effective agent for SLN mapping, has emerged as the most recommended tracer for intraoperative detection of SLN in EC owing to its higher sensitivity and specificity compared with conventional tracers (blue dye and radiotracer)
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Trial description 22/01/2026 PACTR Admin This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. Back ground: Endometrial cancer (EC) is the most common gynecological malignancy of the female genital tract in developed countries. In terms of mortality of female genital tract cancers, the rate of EC is the second highest worldwide. High-grade EC include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated/dedifferentiated carcinomas, and carcinosarcoma. They metastasize via the lymphatic system. In contrast, low-grade type 1 endometrioid carcinomas tend to remain confined to the uterus. Lymph node (LN) metastasis is the primary route of metastasis of malignant uterine tumors as well as the main recurrence cause and the main risk factors of lymphatic involvement are myometrial involvement and histologic grade. Lymph node assessment as a staging procedure has been clinically important in evaluating the disease extent and providing prognostic information, which may help in deciding adjuvant treatments. Lymphadenectomy in high-grade EC histotypes, was associated with improved overall and recurrence free survival. Regarding extensive systemic lymphadenectomy, A study of the treatment of cancer of the womb (ASTEC) trial and the Italian collaborative trial reported a considerable increase in lymphatic dissection complications (relative risk [RR]: 3.73; 95% CI: 1.04−13.27) and surgical morbidity (RR: 8.39; 95% CI: 4.06−17.33). Although SLNB has gained acceptance in the context of low-grade EC, its role in high-grade EC remains unclear. Fluorescent dye Indocyanine green (ICG), a safe and effective agent for SLN mapping, has emerged as the most recommended tracer for intraoperative detection of SLN in EC owing to its higher sensitivity and specificity compared with conventional tracers (blue dye and radiotracer) Back ground: Endometrial cancer (EC) is the most common gynecological malignancy of the female genital tract in developed countries. In terms of mortality of female genital tract cancers, the rate of EC is the second highest worldwide. High-grade EC include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated/dedifferentiated carcinomas, and carcinosarcoma. They metastasize via the lymphatic system. In contrast, low-grade type 1 endometrioid carcinomas tend to remain confined to the uterus. Lymph node (LN) metastasis is the primary route of metastasis of malignant uterine tumors as well as the main recurrence cause and the main risk factors of lymphatic involvement are myometrial involvement and histologic grade. Lymph node assessment as a staging procedure has been clinically important in evaluating the disease extent and providing prognostic information, which may help in deciding adjuvant treatments. Lymphadenectomy in high-grade EC histotypes, was associated with improved overall and recurrence free survival. Regarding extensive systemic lymphadenectomy, A study of the treatment of cancer of the womb (ASTEC) trial and the Italian collaborative trial reported a considerable increase in lymphatic dissection complications (relative risk [RR]: 3.73; 95% CI: 1.04−13.27) and surgical morbidity (RR: 8.39; 95% CI: 4.06−17.33). Although SLNB has gained acceptance in the context of low-grade EC, its role in high-grade EC remains unclear. Fluorescent dye Indocyanine green (ICG), a safe and effective agent for SLN mapping, has emerged as the most recommended tracer for intraoperative detection of SLN in EC owing to its higher sensitivity and specificity compared with conventional tracers (blue dye and radiotracer). This is a single center prospective cohort study, will be conducted on 39 patients with clinically node negative pathologically proven intermediate and high grade endometrial cancer. Our study aims to evaluate overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer.
Section Name Field Name Date Reason Old Value Updated Value
Eligibility Age group 29/12/2025 the reviewer asked to tick all applicable age group including the minimum age Adult: 19 Year-44 Year, Middle Aged: 45 Year(s)-64 Year(s), Aged: 65+ Year(s), 80 and over: 80+ Year Adolescent: 13 Year-18 Year, Adult: 19 Year-44 Year, Middle Aged: 45 Year(s)-64 Year(s), Aged: 65+ Year(s), 80 and over: 80+ Year
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 29/12/2025 the reviewer to specify when outcomes will be measured Primary Outcome, Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high-grade endometrial cancer. this outcome will be measured post operative after paraffin result , both will be measured after paraffin result postoperatively Primary Outcome, Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high-grade endometrial cancer. this outcome will be measured post operative after paraffin result , both outcomes will be measured after paraffin result postoperatively
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 29/12/2025 the reviewer to specify when outcomes will be measured Primary Outcome, Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. , 1- Overall detection rate of ICG SLNB 2- Bilateral detection rate of ICG SLNB in patients with intermediate and high grade endometrial cancer Primary Outcome, Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high-grade endometrial cancer. this outcome will be measured post operative after paraffin result , 1- Overall detection rate of ICG SLNB 2- Bilateral detection rate of ICG SLNB in patients with intermediate and high grade endometrial cancer both will be measured after paraffin result postoperativ
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 29/12/2025 the reviewer to specify when outcomes will be measured Primary Outcome, Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high-grade endometrial cancer. this outcome will be measured post operative after paraffin result , 1- Overall detection rate of ICG SLNB 2- Bilateral detection rate of ICG SLNB in patients with intermediate and high grade endometrial cancer both will be measured after paraffin result postoperativ Primary Outcome, Evaluation of overall and bilateral detection rate of SLNB using ICG, so this will help to determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high-grade endometrial cancer. this outcome will be measured post operative after paraffin result , both will be measured after paraffin result postoperatively
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 29/12/2025 the reviewer asked to specify time when this outcome will be measured Secondary Outcome, Determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. , 1- If SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. Secondary Outcome, Determine whether SLN biopsy, using ICG, could, in the future, replace systemic lymphadenectomy for surgical staging of intermediate and high grade endometrial cancer. , At the end of the study when all data of the participant collected and statistically analysed
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 22/01/2026 The reviewer asked to clarify if the ethics approval for 1 year and i am planning to start in 2026, actually the ethics approval has no time limit as showed in attached IRB letter which i obtained in 2024, yet the study will start in 2026 for 2 years duration TRUE, Medical Research Ethics Committee Institutional Review Board Mansoura Faculty of Medicine Mansoura University, Al Gomhorya street, Mansoura , 92361, Egypt, , 16 Sep 2024, +201092127930, IRB.MFM@hotmail.com, 39689_38040_4737.pdf
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 22/01/2026 The reviewer asked to clarify if the ethics approval for 1 year and i am planning to start in 2026, actually the ethics approval has no time limit as showed in attached IRB letter which i obtained in 2024, yet the study will start in 2026 for 2 years duration TRUE, Medical Research Ethics Committee Institutional Review Board Mansoura Faculty of Medicine Mansoura University, Al Gomhorya street, Mansoura , 92361, Egypt, , 16 Sep 2024, +201092127930, IRB.MFM@hotmail.com, 39689_38040_4737.pdf TRUE, Medical Research Ethics Committee Institutional Review Board Mansoura Faculty of Medicine Mansoura University, Al Gomhorya street, Mansoura , 35516, Egypt, , 16 Sep 2024, +201092127930, IRB.MFM@hotmail.com, 39689_38040_4737.pdf
Section Name Field Name Date Reason Old Value Updated Value
Ethics Ethics List 18/02/2026 the reviewer asked for extension letter TRUE, Medical Research Ethics Committee Institutional Review Board, AlGomhorya street, Mansoura, 35516, Egypt, , 01 Feb 2026, +20502202773, irb_staff@mans.edu.eg, 39689_38149_4737.pdf
Section Name Field Name Date Reason Old Value Updated Value
Funding Source FundingSources List 29/12/2025 the reviewer asked for the actual name of funding sourse Self , Gehan Al sadat Street, Mansoura, , Egypt, Self Funded, Samar Abdallah , Gehan Al sadat Street, Mansoura, , Egypt, Self Funded,